Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
DHES0815A
i
Other names:
DHES0815A, DHES-0815A, RG6148
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Roche
Drug class:
HER2-targeted antibody-drug conjugate, DNA replication inhibitor
Related drugs:
‹
ado-trastuzumab emtansine (97)
fam-trastuzumab deruxtecan-nxki (90)
disitamab vedotin (27)
SHR-A1811 (15)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
MM-302 (4)
PF-06804103 (4)
SBT6050 (4)
BNT323 (4)
BL-M07D1 (3)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
PRO1102 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DAN-311 (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
BAT8010 (0)
DX126-262 (0)
GQ1007 (0)
IBI-354 (0)
JSKN003 (0)
SHR-4602 (0)
(0)
TQB2102 (0)
BI-CON-02 (0)
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
ado-trastuzumab emtansine (97)
fam-trastuzumab deruxtecan-nxki (90)
disitamab vedotin (27)
SHR-A1811 (15)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
MM-302 (4)
PF-06804103 (4)
SBT6050 (4)
BNT323 (4)
BL-M07D1 (3)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
PRO1102 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DAN-311 (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
BAT8010 (0)
DX126-262 (0)
GQ1007 (0)
IBI-354 (0)
JSKN003 (0)
SHR-4602 (0)
(0)
TQB2102 (0)
BI-CON-02 (0)
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 overexpression
Endometrial Cancer
HER-2 overexpression
Endometrial Cancer
DHES0815A
Sensitive: D – Preclinical
DHES0815A
Sensitive
:
D
DHES0815A
Sensitive: D – Preclinical
DHES0815A
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login